Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here


Payment Information We Accept Visa, Mastercard, American Express and Discover


By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

Novo to Acquire Another Obesity Company; Zealand Receives Priority Review for Dasiglucagon CHI NDA

Here is a brief preview of this blast: Two cardiometabolic-related news items have been observed: Embark Laboratories announced that Novo Nordisk acquired the company and its lead obesity asset (view press release); and Zealand announced FDA granted priority review for its dasiglucagon NDA for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age or older with congenital hyperinsulinism (CHI; view press release). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.